This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



rupatadine (Rupafin®)


Reference No. 1755

Publication date:
13/08/2012


Appraisal information

rupatadine (Rupafin®) 1 mg/ml oral solution


Company: GlaxoSmithKline
BNF category: Respiratory system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 07/08/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, rupatadine (Rupafin®) 1 mg/ml oral solution cannot be endorsed for use within NHS Wales for the treatment of symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis) in children aged 6 to 11 years.
Statement of Advice (SOA)
Download